ArticlesComparison of acamprosate and placebo in long-term treatment of alcohol dependence
References (29)
- et al.
A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?
Pharmacol Biochem Behav
(1984) - et al.
Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats
Pharmacol Biochem Behav
(1992) - et al.
Acamprosate (calcium acetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors
Eur J Pharmacol
(1993) - et al.
Dose-dependent suppression of the alcohol intake on chronically intoxicated rats by Ca-acetyl homotaurinate
Alcohol
(1987) - et al.
Ability of calcium bis acetyl homotaurine, a GABA agonist to prevent relapse in weaned alcoholics
Lancet
(1985) - et al.
Effects of fluoxetine and CA-acetyl-homotaurinate on alcohol intake in familial and non-familial alcoholic patients
Curr Ther Res
(1992) - et al.
The effectiveness of alcoholism treatment methods: what research reveals
- et al.
Naltrexone in the treatment of alcohol dependence
Arch Gen Psychiatr
(1992) - et al.
Naltrexone and coping skills therapy for alcohol dependence
Arch Gen Psychiatry
(1992) - et al.
A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence
Alcohol Clin Exp Res
(1994)
Possible pharmacological probes for predicting and preventing relapse in treated alcoholics
Alcohol-Alcohol Suppl
(1991)
Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence
Alcoholism Clin Exp Res
(1994)
Tiapride in the prevention of relapse in recently detoxified alcoholics
Br J Psychiatry
(1994)
Bromocriptine in the prevention of alcohol abuse
Acta Psychiatr Scand
(1983)
Cited by (271)
Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?
2022, European Journal of Internal MedicineComorbid alcohol use and post-traumatic stress disorders: Pharmacotherapy with aldehyde dehydrogenase 2 inhibitors versus current agents
2022, Progress in Neuro-Psychopharmacology and Biological PsychiatryMetabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder
2017, Neuroscience and Biobehavioral ReviewsCitation Excerpt :Acamprosate is known to affect two neurotransmitter systems, including GABA (as an agonist) and glutamate (as a NMDAR as well as mGluR5 antagonist). The drug was effective in increasing the complete abstinence rate as well as cumulative abstinence duration in several long-term placebo-controlled trials in alcohol-dependent patients (Lhuintre et al., 1990; Paille et al., 1995; Sass et al., 1996; Whitworth et al., 1996). However, in a large clinical trial involving 1383 patients in nine possible treatment groups, acamprosate neither alone nor with naltrexone or combined behavioral intervention shows a statistically significant reduction in alcohol consumption over placebo (Anton et al., 2006).
The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study
2016, Journal of Substance Abuse Treatment
Copyright © 1996 Published by Elsevier Ltd.